Implant improves vision for patients suffering from macular degeneration

NewsGuard 100/100 Score

Physicians at the Virginia Commonwealth University Medical Center have become the first in Virginia to successfully implant a telescope in a patient's eye to treat macular degeneration.

The telescope implant is designed to correct end-stage age-related macular degeneration (AMD), the most advanced form of AMD and the leading cause of blindness in older Americans. Patients with end-stage AMD have a central blind spot. This vision loss makes it difficult or impossible to see faces, to read and to perform everyday activities such as watching television, preparing meals and self-care.

William H. Benson, M.D., a cornea specialist and chairman of the Department of Ophthalmology at the VCU School of Medicine, performed the procedure.

"We are excited to provide this new surgical option to our advanced macular degeneration patients, who up until now have had limited options for improving vision," Benson said. "Advanced macular degeneration is a devastating disease, which cannot be treated by any available drugs or surgical procedures. The telescope implant offers a new hope for patients with limited vision."

Smaller than a pea, the telescope implant uses micro-optical technology to magnify images that would normally be seen in one's "straight ahead" or central vision. The images are projected onto the healthy portion of the retina not affected by the disease, making it possible for patients to see or discern the central vision object of interest.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Pitt researchers uncover mechanisms behind uveal melanoma resistance